The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

AML18 trial: How should gemtuzumab ozogamicin be applied in AML?

Jun 16, 2020

During the 25th Congress of the European Hematology Association (EHA), the AML Hub spoke to Nigel Russell, Guy's and St Thomas' NHS Foundation Trust, London, UK. We asked: How should gemtuzumab ozogamicin be applied in AML?

Here, Nigel Russell discusses the treatment of elderly patients with AML with the CD33-targeted antibody–drug conjugate, gemtuzumab ozogamicin, as part of the AML18 trial. The overall survival and response rates demonstrated by patients, who were randomized to receive either a single dose or a fractionated dosing schedule of gemtuzumab ozogamicin, are outlined.

AML18 trial: How should gemtuzumab ozogamicin be applied in AML?